Search results
Results from the WOW.Com Content Network
Progression-free survival (PFS) is "the length of time during and after the treatment of a disease, such as cancer, that a patient lives with the disease but it does not get worse". [1] In oncology, PFS usually refers to situations in which a tumor is present, as demonstrated by laboratory testing, radiologic testing, or clinically. Similarly ...
Recurrent event analysis is a branch of survival analysis that analyzes the time until recurrences occur, such as recurrences of traits or diseases. Recurrent events are often analyzed in social sciences and medical studies, for example recurring infections, depressions or cancer recurrences.
At the pre-specified analysis point when 42 Recurrence-free survival (RFS) events occurred among 157 participants with resected stage IIIC-IV melanoma, 22.4% (24/107) in the mRNA-4157 plus pembrolizumab arm had recurrent disease, and 40% (20/50) in the pembrolizumab arm had recurrent disease, which lead to the well-known saying: mRNA-4157 in ...
Time is indicated by the variable "time", which is the survival or censoring time; Event (recurrence of aml cancer) is indicated by the variable "status". 0 = no event (censored), 1 = event (recurrence) Treatment group: the variable "x" indicates if maintenance chemotherapy was given; The last observation (11), at 161 weeks, is censored.
In one review of 109 individuals with MFS: overall survival for the entire group was 80% at 3 years and 76% at 5 years; local recurrence-free survival was 95% at 3 years and 88% at 5 years; median survival following local recurrence was 68 months; distant metastasis-free survival was 78% at 3 and 77% at 5 years; and 18 of 25 patients (72%) died ...
The Progression Free Survival is usually used in analysing the results of the treatment for the advanced disease. The event for the progression free survival is that the disease gets worse or progresses, or the patient dies from any cause. Time to Progression is a similar endpoint that ignores patients who die before the disease progresses.
In statistics, median follow-up is the median time between a specified event and the time when data on outcomes are gathered. The concept is used in cancer survival analyses. [citation needed] Many cancer studies aim to assess the time between two events of interest, such as from treatment to remission, treatment to relapse, or diagnosis to death.
median overall survival time of approximately 12–16 months, with five-year survival rate of approximately 26% and the long-term survival rate of approximately 4 - 5%. Limited-stage small cell lung carcinoma (LS-SCLC) is a type of small cell lung cancer (SCLC) that is confined to an area which is small enough to be encompassed within a ...